Research output per year
Research output per year
Fingerprint
Dive into the research topics where David Peng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Moreno Diaz, B. A., Lyu, H., Peng, D. H., Khazaei, S., Schalck, A., Zhou, X., Sugimoto, H., Bickert, A. A., Sthanam, L. K., Taylor, M. R. & Kumbhar, S. V. & 12 others, , Aug 17 2026, In: EMBO Journal. 45, 16, p. 5727-5758 32 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
McAndrews, K. M., Paradiso, F., Stalnecker, C. A., Chellakkan, B. S., Thege, F. I., Peng, D. H., Moreno Diaz, B. A., Sugimoto, H., Patel, S. I., Mahadevan, K. K., Kirtley, M. L., Wills, D., Sockwell, A. M., Fonseca, A. L. F., Liu, Y., Rajapakshe, K. I., Yee, N. G., Tran, P. T., Omar, H. A. & Tedeschi, A. & 25 others, , Sep 3 2025, In: Science translational medicine. 17, 814, eadt5511.Research output: Contribution to journal › Article › peer-review
Open Access12 Link opens in a new tab Scopus citations -
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
House, N. C., Chen, M. M., Khazaei, S., Brown, V., Ramsden, P., Peng, D. H., Moore, S., Yuan, L., Wu, R., Wang, F., Luo, L., Feng, N., Bristow, C. A., Yap, T. A., Keyomarsi, K., Marszalek, J. R., Ribich, S., Rinne, M. L., Muthuswamy, L. B. & Faia, K. L., Dec 2025, In: npj Breast Cancer. 11, 1, 135.Research output: Contribution to journal › Article › peer-review
Open Access10 Link opens in a new tab Scopus citations -
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E. Y., Yao, J., Xun, Z., Nguyen, P. T., Wang, X., Yang, Z., Yousef, A., Pan, D., Jin, Y., Li, C. F., Theardy, M. S., Park, J., Cai, Y., Takeda, M., Vasquez, M., Park, E. M., Peng, D. H. & Zhou, Y. & 10 others, , Dec 1 2025, In: Cancer Research. 85, 23, p. 4825-4838 14 p.Research output: Contribution to journal › Article › peer-review
3 Link opens in a new tab Scopus citations -
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Soeung, M., Yan, X., Zanca, C., Qian, J., Karki, M., Duan, F., Khan, H., Zhang, L., Peng, D. H., Williams, M., He, R., Chen, Z., Perelli, L., Chen, J., Tidwell, R. S., Chauhan, P. K., Le, C. N., Lam, T. N. A., Bhattacharya, N. & Shah, R. & 46 others, , Dec 2025, In: Nature communications. 16, 1, 10474.Research output: Contribution to journal › Article › peer-review
Open Access7 Link opens in a new tab Scopus citations